 | • レポートコード：MRC2203A268 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界の複合性局所疼痛症候群（CRPS）市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患種類別（CRPS I、CRPS II、CRPS-NOS）分析、治療種類別（医薬品、脊髄刺激、外科的交感神経切除術、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の複合性局所疼痛症候群（CRPS）市場規模：疾患種類別（CRPS I、CRPS II、CRPS-NOS） ・世界の複合性局所疼痛症候群（CRPS）市場規模：治療種類別（医薬品、脊髄刺激、外科的交感神経切除術、その他） ・世界の複合性局所疼痛症候群（CRPS）市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Allergan、Boston Scientific Corporation、GlaxoSmithKline plc.、…） ・市場機会・将来傾向 |
The global complex regional pain syndrome market studied was anticipated to grow with a CAGR of nearly 2.1% during the forecast period. CRPS is a condition of chronic pain that affects legs, arms, feet, and hands; which occurs after an injury. It is categorized into two types: CRPS-I and CRPS-II. Individuals who don’t have confirmed nerves injury are classified in CRPS-I and those who have confirmed nerve associated injury are classified in CRPS-II.
Rise in the number of patients suffering from complex regional pain syndrome (CRPS), chronic pain and failed back syndrome are the key factors boosting the market growth. According to the National Institute of Neurological Disorders and Stroke (NINDS), CRPS is commonly found in women and can occur in any age. In addition, 90 percent of cases triggered due to trauma and injury. Thus, an increasing number of patients suffering from chronic pain drive market growth.
Moreover, rising number of initiatives undertaken by nonprofit organizations, an increase in R&D funding by both private & public organizations and supportive government legislation are some of the crucial factors expected to drive the market in the coming few years. For instance, The International Research Foundation for RDS/ CRPS established an international research network which will help to educate medical professional and support research.
Rising number of potential clinical pipeline candidates is one of the key factors expected to propel the market growth. Moreover, upsurge in number of clinical trials to expand its target patient base with the existing drug portfolio is also amongst some of the drivers of this market. Growing R&D activities are expected to propel market growth. Some of the pipelined drugs are NKTR-181, Upadacitinib, Golodirsen and Tafamidis meglumine. However, lack of awareness about target disease in developing countries may restrain the growth of the market.
Key Market Trends
CRPS I Dominates the Market and is Expected to Continue to Do the Same during the Forecast Period
- CRPS I is expected to dominate the market through the forecast period. Individuals without a confirmed nerve injury are classified as having CRPS-I (previously known as reflex sympathetic dystrophy syndrome). This can be attributed to the rise in number of patients suffering from complex regional pain syndrome type 1. According to the Mayo Foundation for Medical Education and Research, about 90% of people with CRPS have type 1. Thus, the increasing number of patients suffering from chronic pain drive market growth.
- Thus, the segment is witnessing a shift toward combination therapies that provide enhanced results to patients. Higher availability for treatment, positive results and reimbursement policies by key players for the target disease are supplementing the growth of the segment. Focus on developing new drugs to address the changing needs of the patients in the treatment poised to create a significant shift in prescription patterns.
North America Represents the Largest Market and Asia-Pacific is Expected to Register Fastest Growth.
North America is at the forefront of growth in the region and is also an important revenue contributor in the global arena. Heightened awareness of disease remittance therapies among patients, rising prevalence of CRPS, and high public and private healthcare spending are stimulating the growth of the region. Moreover, easy access to quality healthcare, favorable reimbursement policies, strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America.
The Asia Pacific is likely to post the fastest market throughout the forecast horizon. Growing adoption of urban lifestyle is leading to an expanding the base of patients in the region. This, coupled with increasing healthcare spending, is expected to propel the market in APAC. Favorable regulatory policies for drug approval are estimated to boost demand for the regional market over the forecast period.
Competitive Landscape
Investment in R&D is one of the strategic measures to beat the competition. The key players in this market are Allergan, Boston Scientific Corporation, GlaxoSmithKline plc., ICU Medical, Johnson & Johnson and Medtronic.
The players operating in the market focus on introducing new products to address the changing need of the patients. For instance, Medtronic implantable neurostimulation system, which is designed to reduce the chronic pain of the limb or of the trunk. It is used for the treatment of failed back syndrome, post laminectomy pain, peripheral causalgia, epidural fibrosis, unsuccessful disk surgery, and CRPS.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Complex Regional Pain Syndrome
4.2.2 Increase in Number of Patients Suffering from Chronic Pain
4.3 Market Restraints
4.3.1 Lack of Awareness about Target Disease in Developing Countries
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Disease Type
5.1.1 CRPS I
5.1.2 CRPS II
5.1.3 CRPS-NOS
5.2 By Therapy Type
5.2.1 Drugs
5.2.1.1 Analgesics
5.2.1.2 Antidepressants
5.2.1.3 Corticosteroids
5.2.2 Spinal Cord Stimulation
5.2.3 Surgical Sympathectomy
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allergan
6.1.2 Boston Scientific Corporation
6.1.3 GlaxoSmithKline plc.
6.1.4 ICU Medical
6.1.5 Johnson & Johnson
6.1.6 Medtronic Plc
6.1.7 Viatris
6.1.8 Nevro Corp.
6.1.9 Purdue Pharma
6.1.10 Sanofi S.A
7 MARKET OPPORTUNITIES AND FUTURE TRENDS